Raphas Co. Ltd (214260) - Total Assets
Based on the latest financial reports, Raphas Co. Ltd (214260) holds total assets worth ₩82.76 Billion KRW (≈ $56.08 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 214260 book value for net asset value and shareholders' equity analysis.
Raphas Co. Ltd - Total Assets Trend (2017–2024)
This chart illustrates how Raphas Co. Ltd's total assets have evolved over time, based on quarterly financial data.
Raphas Co. Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Raphas Co. Ltd's total assets of ₩82.76 Billion consist of 42.1% current assets and 57.9% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩1.11 Billion | 17.5% |
| Accounts Receivable | ₩3.23 Billion | 4.3% |
| Inventory | ₩5.38 Billion | 7.1% |
| Property, Plant & Equipment | ₩29.87 Billion | 39.3% |
| Intangible Assets | ₩3.21 Billion | 4.2% |
| Goodwill | ₩2.07 Billion | 2.7% |
Asset Composition Trend (2017–2024)
This chart illustrates how Raphas Co. Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 214260 market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Raphas Co. Ltd's current assets represent 42.1% of total assets in 2024, a decrease from 44.3% in 2017.
- Cash Position: Cash and equivalents constituted 17.5% of total assets in 2024, up from 6.8% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 1.0% in 2017.
- Asset Diversification: The largest asset category is property, plant & equipment at 39.3% of total assets.
Raphas Co. Ltd Competitors by Total Assets
Key competitors of Raphas Co. Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Raphas Co. Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.83 | 0.69 | 4.92 |
| Quick Ratio | 0.72 | 0.59 | 4.50 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩-7.68 Billion | ₩-15.71 Billion | ₩21.10 Billion |
Raphas Co. Ltd - Advanced Valuation Insights
This section examines the relationship between Raphas Co. Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.26 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -24.2% |
| Total Assets | ₩76.09 Billion |
| Market Capitalization | $54.13 Million USD |
Valuation Analysis
Below Book Valuation: The market values Raphas Co. Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Raphas Co. Ltd's assets decreased by 24.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Raphas Co. Ltd (2017–2024)
The table below shows the annual total assets of Raphas Co. Ltd from 2017 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩76.09 Billion ≈ $51.57 Million |
-24.21% |
| 2023-12-31 | ₩100.40 Billion ≈ $68.04 Million |
+4.52% |
| 2022-12-31 | ₩96.06 Billion ≈ $65.10 Million |
-1.82% |
| 2021-12-31 | ₩97.84 Billion ≈ $66.31 Million |
+63.54% |
| 2020-12-31 | ₩59.83 Billion ≈ $40.54 Million |
-4.86% |
| 2019-12-31 | ₩62.88 Billion ≈ $42.62 Million |
+82.20% |
| 2018-12-31 | ₩34.51 Billion ≈ $23.39 Million |
-0.86% |
| 2017-12-31 | ₩34.81 Billion ≈ $23.59 Million |
-- |
About Raphas Co. Ltd
Raphas Co., Ltd. manufactures and sells biodegradable microneedles in Korea. The company offers skin care, medical device, whitening care, and wrinkle care under the Acropass brand; and health food product under the FitKong brand. It also supplies double-layer microneedle manufacturing technology; and provides original development manufacturing, and contract development and manufacturing organiza… Read more